Correlation of O<sup>6</sup>-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

Monika E. Hegi(University Hospital of Lausanne), Mark R. Gilbert(National Institutes of Health), James G. Herman, Roger Stupp(University Hospital of Zurich), Wolfgang Wick(Hertie Institute for Clinical Brain Research), Michael Weller(University of Zurich), Lili Liu(Johns Hopkins University), Minesh P. Mehta(Columbia University)
Journal of Clinical Oncology
September 1, 2008
10.1200/jco.2007.11.5964
Cited by 805

Related Papers

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
|JAMA|2017|2.5k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Inactivation of the DNA-Repair Gene<i>MGMT</i>and the Clinical Response of Gliomas to Alkylating Agents
|New England Journal of Medicine|2000|2.2k